Related Experiment Video
Updated: Sep 11, 2025
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential
Hongling Chu1,2, Yanling Ding3, Yunxian Zhou4
1Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Introduction:
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and progressive lung disease with a significant impact on patients' quality of life. While much research has focused on disease mechanisms and treatment efficacy, limited attention has been paid to the landscape, unmet needs, patient experiences and quality of life. Understanding these aspects through the patient journey is essential for developing patient-centred therapeutic strategies. Therefore, this study aims to explore the status of diagnosis, treatment, the unmet needs and patient experiences of IPF in China through an analysis of the patient journey using mixed methods research. The findings in this study provide valuable insights to guide drug development, optimise clinical decision-making and support health technology assessments.
Methods And Analysis:
An exploratory sequential mixed methods design will be used in two phases. In the qualitative phase, 50 patients with IPF and 15 experienced physicians will be recruited to complete in-depth interviews. Patient journey and unmet medical needs will be the focus of data collection. Based on the findings of the qualitative study, a structured questionnaire will be developed for the subsequent quantitative study. Data will be collected from 245 patients with IPF to quantitatively analyse critical points in the patient journey, quality of life, unmet needs and treatment expectations. The integration of patient experience data into the drug/intervention development lifecycle in this mixed methods research will enhance the relevance of IPF interventions, optimising disease management strategies and improving patient health outcomes.
Ethics And Dissemination:
The study has been approved by the Peking University Third Hospital Medical Science Research Ethics Committee (2024-188-02). Prior to the study, study information will be provided, and consent will be obtained. Findings in this study will be disseminated in peer-reviewed publications and conferences.
Trial Registration Number:
NCT06629623.
Related Concept Videos
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation